Moderna, Inc. (NASDAQ:MRNA) Given Consensus Recommendation of “Hold” by Analysts

Shares of Moderna, Inc. (NASDAQ:MRNA) have been given a consensus rating of “Hold” by the twenty-two brokerages that are covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a sell recommendation, twelve have assigned a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $78.83.

MRNA has been the subject of several research reports. Berenberg Bank assumed coverage on shares of Moderna in a research report on Tuesday, November 19th. They set a “hold” rating and a $42.00 price objective for the company. Royal Bank of Canada restated a “sector perform” rating and issued a $75.00 price target on shares of Moderna in a research note on Thursday, September 19th. HSBC upgraded Moderna from a “hold” rating to a “buy” rating and set a $58.00 price objective on the stock in a research report on Monday, November 18th. UBS Group reduced their target price on shares of Moderna from $108.00 to $96.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, Barclays dropped their price objective on shares of Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a research note on Friday, November 8th.

Insider Activity at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the sale, the insider now owns 19,717 shares in the company, valued at $843,690.43. The trade was a 6.71 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last three months, insiders have sold 2,664 shares of company stock valued at $115,210. 15.70% of the stock is owned by insiders.

Institutional Trading of Moderna

A number of hedge funds have recently made changes to their positions in MRNA. Larson Financial Group LLC grew its holdings in Moderna by 1,753.1% during the 2nd quarter. Larson Financial Group LLC now owns 593 shares of the company’s stock worth $70,000 after acquiring an additional 561 shares during the last quarter. TD Asset Management Inc grew its stake in shares of Moderna by 13.8% in the second quarter. TD Asset Management Inc now owns 162,137 shares of the company’s stock worth $19,254,000 after purchasing an additional 19,599 shares during the last quarter. Private Advisor Group LLC increased its holdings in Moderna by 112.1% in the second quarter. Private Advisor Group LLC now owns 30,733 shares of the company’s stock valued at $3,650,000 after purchasing an additional 16,243 shares during the period. Lake Street Advisors Group LLC raised its position in Moderna by 6.8% during the 2nd quarter. Lake Street Advisors Group LLC now owns 3,991 shares of the company’s stock worth $474,000 after purchasing an additional 253 shares during the last quarter. Finally, Asset Dedication LLC lifted its holdings in Moderna by 41.8% during the 2nd quarter. Asset Dedication LLC now owns 1,018 shares of the company’s stock worth $121,000 after buying an additional 300 shares during the period. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Stock Down 2.1 %

MRNA stock opened at $42.25 on Tuesday. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $16.26 billion, a PE ratio of -7.26 and a beta of 1.60. Moderna has a 1-year low of $35.80 and a 1-year high of $170.47. The business’s 50 day simple moving average is $42.52 and its 200 day simple moving average is $69.36.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($1.89) by $1.92. The firm had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company’s quarterly revenue was up 3.8% on a year-over-year basis. During the same period in the previous year, the company earned ($1.39) earnings per share. As a group, research analysts anticipate that Moderna will post -9.3 EPS for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.